{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7","upperLimit":"21.0","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Time from date of treatment start until the date of first objective documentation of disease-relapse.","dispersionType":"Full Range","groups":[{"description":"Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nErlotinib Hydrochloride: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Treatment (Erlotinib Hydrochloride)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 21 weeks","title":"Event-free Survival","type":"PRIMARY","unitOfMeasure":"Weeks"}